Benzimidazole based hybrids against complex diseases: A catalogue of the SAR profile

被引:32
作者
Choudhary, Shalki [1 ]
Arora, Mohit [1 ]
Verma, Himanshu [1 ]
Kumar, Manoj [1 ]
Silakari, Om [1 ]
机构
[1] Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Mol Modelling Lab MML, Patiala 147002, Punjab, India
关键词
Benzimidazole; Hybrids; Multi-factorial; SAR; Pathophysiology; DESIGNED MULTIPLE LIGANDS; PROTON-PUMP INHIBITOR; IN-VITRO EVALUATION; BIOLOGICAL EVALUATION; POTENTIAL ANTICANCER; PHARMACOLOGICAL EVALUATION; MOLECULAR HYBRIDIZATION; DNA INTERACTION; DOUBLE-BLIND; DRUG DESIGN;
D O I
10.1016/j.ejphar.2021.174027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The fused heterocyclic ring system has been recognized as a privileged structure that is used as a template in medicinal chemistry for drug discovery. Benzimidazole is one of the common scaffolds found in several natural products such as histidine, purines, and an integral part of vitamin B12. This hetero-aromatic bicyclic ring system acts as a pharmacophore in various drugs of therapeutic interest and has a broad spectrum of activity. Literature reports suggest that diversely substituted benzimidazoles possess distinct pharmacological profiles with multitargeting potential, thereby, an indispensable anchor for the development of novel therapeutic agents against complex diseases such as cancer, malaria, inflammatory disorders, microbial diseases, hypertension, etc. Thus, lots of efforts have been diverted towards exploring the therapeutic potential of benzimidazoles. Despite great efforts made by the research community, still, some multi-factorial diseases continue to progress due to their complex pathophysiology. Under these sets of circumstances, there is a need to explore this nucleus for hybrid designing with multi-targeting potential against complex diseases. Benzimidazole-based hybrids have been reported to treat multifactorial diseases, making it a scaffold of interest for various pharmaceutical companies and research groups. In this write-up, we shed light on the recent pharmacological profiles, various designing strategies, and structure-activity relationships (SAR) of different benzimidazole-based hybrids.
引用
收藏
页数:19
相关论文
共 106 条
[1]   NEW BROAD SPECTRUM ANTHELMINTIC METHYL 5(6)-BUTYL-2-BENZIMIDAZOLECARBAMATE [J].
ACTOR, P ;
ANDERSON, EL ;
DICUOLLO, CJ ;
FERLAUTO, RJ ;
HOOVER, JRE ;
PAGANO, JF ;
RAVIN, LR ;
SCHEIDY, SF ;
STEDMAN, RJ ;
THEODORI.VJ .
NATURE, 1967, 215 (5098) :321-&
[2]  
Agarwal D, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00249-17, 10.1128/aac.00249-17]
[3]  
Alagoz M., 2020, ANN MED RES, V27, P266, DOI 10.5455/annalsmedres.2019.09.510
[4]   Novel coumarin benzimidazole derivatives as antioxidants and safer anti-inflammatory agents [J].
Arora, Radha Krishan ;
Kaur, Navneet ;
Bansal, Yogita ;
Bansal, Gulshan .
ACTA PHARMACEUTICA SINICA B, 2014, 4 (05) :368-375
[5]   Novel structural hybrids of pyrazolobenzothiazines with benzimidazoles as cholinesterase inhibitors [J].
Aslam, Sana ;
Zaib, Sumera ;
Ahmad, Matloob ;
Gardiner, John M. ;
Ahmad, Aqeel ;
Hameed, Abdul ;
Furtmann, Norbert ;
Guetschow, Michael ;
Bajorath, Juergen ;
Iqbal, Jamshed .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 78 :106-117
[6]  
Bandyopadhyay U, 1999, CURR SCI INDIA, V77, P658
[7]   Synthesis and pharmacological evaluation of polyfunctional benzimidazole-NSAID chimeric molecules combining anti-inflammatory, immunomodulatory and antioxidant activities [J].
Bansal, Yogita ;
Silakari, Om .
ARCHIVES OF PHARMACAL RESEARCH, 2014, 37 (11) :1426-1436
[8]   The therapeutic journey of benzimidazoles: A review [J].
Bansal, Yogita ;
Silakari, Om .
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (21) :6208-6236
[9]  
Barbato L, 1996, FUNCT NEUROL, V11, P201
[10]   PANTOPRAZOLE - A NOVEL H+/K+-ATPASE INHIBITOR WITH AN IMPROVED PH STABILITY [J].
BEIL, W ;
STAAR, U ;
SEWING, KF .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 218 (2-3) :265-271